Epanova + Lovaza
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Hypertriglyceridemia
Conditions
Severe Hypertriglyceridemia
Trial Timeline
Oct 1, 2014 โ Jul 1, 2015
NCT ID
NCT02189252About Epanova + Lovaza
Epanova + Lovaza is a phase 1 stage product being developed by AstraZeneca for Severe Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02189252. Target conditions include Severe Hypertriglyceridemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02189252 | Phase 1 | Completed |
Competing Products
20 competing products in Severe Hypertriglyceridemia